"This is Sildenafil. ”

"I don't see anything. ”

"You say this drug, it's really interesting, a small gadget, it can sell for hundreds of millions of dollars. ”

A group of laymen surrounded the API of sildenafil and let out bursts of emotion.

Sildenafil, which is used for clinical trials, does not need to be dyed or anything, but is condensed into small tablets with pure white starch and some APIs, which have neither taste nor appearance.

If medical experts are discussing with each other, they can probably talk about something new about acetylcholine.

However, in the eyes of a group of bankers who deal with money all day long, this thing looks so empty.

"Professor Yang is here. Someone caught a glimpse of Yang Rui and immediately shouted.

Several bank cadres of the Chinese Agricultural Construction Industry immediately straightened up and showed cordial smiles.

"Professor Yang is here. ”

"Congratulations on making the medicine. ”

"Good luck with your experiment. ”

Several cadres seemed to be greeting the New Year, and they were giving up their hands and saying auspicious words.

What you said was really sincere.

Although Pfizer finally sold sildenafil to Yang Rui, it was a high price, adding $180 million! Moreover, it is a milestone - if a finished blood pressure drug is made, whether it is marketed in any country in the world, it will have to add $200 million, and then, if it is marketed in Europe or the United States, it will add $200 million.

It is equivalent to saying that if the antihypertensive drug made of sildenafil starts to be sold in the United States, no matter how much it is sold, Pfizer will take 580 million US dollars.

This is not over, if it sells well, that is, if the annual sales exceed 100 million US dollars, Pfizer will take 18% - 18% of the sales and exchange it into profits, how can there be 20% or 30%, and it is a milestone...... If sales exceed $1 billion and become a blockbuster, Pfizer will take 25% of the sales revenue.

It's just mad.

To be honest, such an offer, that is, Pfizer can offer.

That is, Yang Rui can give it out.

Pharmaceutical companies such as Jielizena may not have such courage.

The highest state of the milestone is $580 million, plus 25% of sales, the latter is achieved with sales of more than $1 billion, which is equivalent to $250 million a year, and the patent term for 15 consecutive years is 3.8 billion without going up.

A patented compound that has only passed the first phase of clinical trials has been sold for 180 million US dollars off the production line, and 3.8 billion yuan has been launched upwards, which is also one of the highest prices in the pharmaceutical industry that has not come for 90 years.

This is still the result of Yang Rui's arguments - of course, in order to focus the milestone on one point of antihypertensive drugs, Yang Rui also put some water a little.

Still, as a compound, the price is high enough.

Even if it is a finished drug, it is very good to sell a few hundred million dollars.

Double-digit transactions are less common.

Even foreign companies such as Jielikang rarely give such a big milestone transaction. For example, Yang Rui's deferiprone is only the starting price of sildenafil, and he still sells 7 active compounds together.

This is the case with large pharmaceutical companies, squeezing small biotech companies on the one hand, and filling the market space with strong capital on the other.

If it weren't for the background of the Chinese market, Yang Rui would not be able to pull a high price.

Of course, the current high price is not a problem for Yang Rui.

All the milestones are for sildenafil's antihypertensive effect, not for other indications, and Pfizer, although not very reluctant to sign up for this, is also pinching its nose and admitting it.

In fact, most of the drugs have additional effects, in professional terms, that is, they can target other indications.

To put it simply, the side effects of drugs can be used as new indications for drugs.

For example, the most common diarrhea.

Diarrhea is a side effect of many medications, but if the effect of diarrhea is good, then drugs that are prone to diarrhea can naturally be used as laxatives.

On the contrary, some drugs can cause constipation in patients, so if the effect of constipation is good, can it be made into antidiarrheal drugs?

For example, among the common side effects of antihypertensive drugs, tachycardia is often included. For many patients, especially elderly patients, this is not good, but for patients with bradycardia, this is not a good thing, so, Da Da, a drug that can treat bradycardia is freshly baked, and its side effect is to lower blood pressure......

In the same way, the side effect of some drugs is to lower the heart rate, so for patients with tachycardia, it can work again.

It can be seen that a panacea is impossible in the era of chemical drugs.

Your medicine can't cause diarrhea and stop diarrhea at the same time, and it can't lower blood pressure and raise blood pressure at the same time, raise and lower heart rate.

Aspirin is already a miracle drug, it can reduce inflammation and pain, cure colds, and inhibit platelets, prevent stroke, even so, try to feed aspirin to the nobles with hemophilia, the other party is willing to break the eight scepters, let you pay for the gems.

For pharmaceutical companies, developing a new indication for a drug is a matter of improving profits.

Because there is no need to do animal experiments and phase I and phase II clinical trials, as long as its efficacy is proven in the third phase of clinical trials, the cost is relatively low.

However, not every drug is a miracle drug like aspirin, and there are not many drugs that can perform well in the development of new indications, and it is naturally not easy to increase sales.

On the other hand, the patent term is not endless, the general patent term of a drug is slightly more than 15 years, and the extra part is usually the additional patent term applied for, but it is also in single digits, in other words, there are very few patented drugs that can be monopolized and sold for 25 years.

The development of new indications increases the "slightly more" part, which is equivalent to exchanging the follow-up costs such as clinical phases III and IV for a single-digit increase in patent periods. Whether it's cost-effective or not, it's not necessarily.

Most of the time, the development of new indications is not so much a finding of a new use of the drug as a small trick by pharmaceutical companies to extend the patent term.

If you think about it deeply, the new indication of the drug is equivalent to the side effects, the better the efficacy of the new indication, the stronger and clearer the side effects, for a drug, this is a double-edged sword, the pharmaceutical company would rather have a drug with minimal side effects and no new indications, and I am afraid that it is not willing to have a drug with strong side effects and a variety of new indications.

Using a movie as an analogy, the original indication of a drug is equivalent to the theater box office, which is the main way for the company to make money. The new indication is equivalent to the sales revenue of DVDs, Blu-ray discs, peripherals, etc., there are some companies that are good at these and make money through this, but after all, they are not mainstream and unstable.

At Yang Rui's insistence, Pfizer gave up part of its later profits and focused on the main revenue part, which also has its own routine.

In terms of profit and loss alone, they have already earned Yang Rui's $180 million from the date of arrival, and the rest is pure profit.

Of course, it is impossible for Yang Rui to come up with $180 million in one go.

Through the coordination of several bigwigs, the money was loaned by Yang Rui in the name of Huarui Company from the four major banks of the Workers' and Peasants' China Construction Bank. Each family bears tens of millions of dollars, and they all turn pale with horror.

Not only that, Yang Rui also has no money to give the milestone of 200 million US dollars and 200 million US dollars in the later stage - the milestone to be given when it goes public is that no matter how much sales are, it is rare to be able to make drugs with annual sales of two or three billion US dollars in the early stage.

Pfizer naturally can't let its well-designed milestones go down the drain, not to mention that Yang Rui doesn't have so much money, even if he has. The development cycle of a drug is often measured in ten years, and during this time, what should he do if he runs out of money?

Therefore, the workers and peasants also have to give Yang Rui a guarantee.

With a total amount of 580 million US dollars, in the eyes of the bank, they are much more risky than Yang Rui.

This can be seen from their attention to the clinical trial center of Hedong University, the four major banks have sent special personnel from the headquarters to take charge of this matter, and after the animal experiment and the repeated experiment of the first phase of the clinical trial are over, there are cadres at the deputy general level to inspect.

There is no way, although the country has slowly gained some money in the past two years, and can afford to pay tens of millions of dollars at every turn, the expenditure of hundreds of millions of dollars is still very powerful. It can be compared with the construction of some basic projects, such as railways, highways, bridges, telecommunication power grids, hydropower stations and so on.

Compared with those projects that can be seen and touched, and can be charged after construction, the research and development of sildenafil is really not worry-free.

Yang Rui was not prepared to let them worry, and the prevention of the needle snapped a triple:

"No one dares to say 100% about scientific research. We will definitely do our best, and everyone should also keep an open mind. ”

"Although our clinical trial center has just been built and is relatively inexperienced, as long as we grasp the opportunity, we will soon become a mature team. ”

"The animal experiments and phase I clinical trials of sildenafil, that is, the safety experiments are very good, and the second phase is a completely unfamiliar blank field, and foreigners have not done it, we are creating history every step of the way, please accompany me to witness. ”

Several senior bank officials are going crazy.

In the past, when I went to inspect the loan company, even if I didn't have the next meal, I would pat my chest and spit out some fresh abalone to prove it.

Is that the attitude you have when it comes to scientific research?

Can you have some confidence?

In the past, it was the loan companies that let us come with confidence.

Witness history?

Who wants to witness history?

Hundreds of millions of dollars!

That's enough to visit how many trips to Paris!

Paris......

Milan......

Long legs......

Grilled elbows......

Bikini......

Blonde ......

A group of bank officials clutched their chests and looked at the large ward behind the single-sided glass, only to feel that their blood pressure could not be controlled.

(End of chapter)